ENSG00000117713 |
|
colon adenocarcinoma |
stop_gained |
9.385% (142/1513) |
8 entries |
ENSG00000117713 |
|
colon adenocarcinoma |
frameshift_variant |
9.385% (142/1513) |
7 entries |
ENSG00000117713 |
|
gastric intestinal type adenocarcinoma |
stop_gained |
19.23% (30/156) |
3 entries |
ENSG00000117713 |
|
ovarian clear cell adenocarcinoma |
conservative_inframe_deletion |
49.77% (109/219) |
2 entries |
ENSG00000117713 |
|
ovarian clear cell adenocarcinoma |
sequence_alteration |
49.77% (109/219) |
3 entries |
ENSG00000117713 |
|
bladder carcinoma |
stop_gained |
18.37% (106/577) |
3 entries |
ENSG00000117713 |
|
female breast carcinoma |
missense_variant |
17.08% (69/404) |
2 entries |
ENSG00000117713 |
|
Endometrial Endometrioid Adenocarcinoma |
conservative_inframe_deletion |
30.34% (311/1025) |
1 entry |
ENSG00000117713 |
|
gastric adenocarcinoma |
stop_gained |
10.93% (115/1052) |
6 entries |
ENSG00000117713 |
|
colon adenocarcinoma |
sequence_alteration |
9.385% (142/1513) |
8 entries |
ENSG00000117713 |
|
urothelial carcinoma |
missense_variant |
35.87% (33/92) |
1 entry |
ENSG00000117713 |
|
Ovarian Endometrioid Adenocarcinoma |
sequence_alteration |
25.33% (19/75) |
2 entries |
ENSG00000117713 |
|
colorectal adenocarcinoma |
sequence_alteration |
10.2% (133/1304) |
4 entries |
ENSG00000117713 |
|
urothelial carcinoma |
frameshift_variant |
35.87% (33/92) |
3 entries |
ENSG00000117713 |
|
gastric intestinal type adenocarcinoma |
frameshift_variant |
19.23% (30/156) |
3 entries |
ENSG00000117713 |
|
Endometrial Endometrioid Adenocarcinoma |
stop_gained |
30.34% (311/1025) |
5 entries |
ENSG00000117713 |
|
bladder transitional cell carcinoma |
missense_variant |
22.12% (165/746) |
10 entries |
ENSG00000117713 |
|
ovarian clear cell adenocarcinoma |
stop_gained |
49.77% (109/219) |
5 entries |
ENSG00000117713 |
|
Ovarian Endometrioid Adenocarcinoma |
stop_gained |
25.33% (19/75) |
4 entries |
ENSG00000117713 |
|
urothelial carcinoma |
stop_gained |
35.87% (33/92) |
1 entry |
ENSG00000117713 |
|
female breast carcinoma |
sequence_alteration |
17.08% (69/404) |
2 entries |
ENSG00000117713 |
|
cecum adenocarcinoma |
sequence_alteration |
13.64% (39/286) |
2 entries |
ENSG00000117713 |
|
bladder carcinoma |
sequence_alteration |
18.37% (106/577) |
1 entry |
ENSG00000117713 |
|
bladder transitional cell carcinoma |
sequence_alteration |
22.12% (165/746) |
7 entries |
ENSG00000117713 |
|
bile duct adenocarcinoma |
conservative_inframe_deletion |
12.4% (77/621) |
2 entries |
ENSG00000117713 |
|
colorectal adenocarcinoma |
stop_gained |
10.2% (133/1304) |
5 entries |
ENSG00000117713 |
|
colorectal adenocarcinoma |
frameshift_variant |
10.2% (133/1304) |
6 entries |
ENSG00000117713 |
|
bile duct adenocarcinoma |
stop_gained |
12.4% (77/621) |
5 entries |
ENSG00000117713 |
|
cecum adenocarcinoma |
frameshift_variant |
13.64% (39/286) |
4 entries |
ENSG00000117713 |
|
gastric intestinal type adenocarcinoma |
missense_variant |
19.23% (30/156) |
2 entries |
ENSG00000117713 |
|
ovarian clear cell adenocarcinoma |
missense_variant |
49.77% (109/219) |
2 entries |
ENSG00000117713 |
|
female breast carcinoma |
gene_fusion |
17.08% (69/404) |
1 entry |
ENSG00000117713 |
|
gastric intestinal type adenocarcinoma |
sequence_alteration |
19.23% (30/156) |
2 entries |
ENSG00000117713 |
|
bladder transitional cell carcinoma |
frameshift_variant |
22.12% (165/746) |
9 entries |
ENSG00000117713 |
|
urothelial carcinoma |
sequence_alteration |
35.87% (33/92) |
2 entries |
ENSG00000117713 |
|
bladder carcinoma |
missense_variant |
18.37% (106/577) |
3 entries |
ENSG00000117713 |
|
gastric adenocarcinoma |
frameshift_variant |
10.93% (115/1052) |
6 entries |
ENSG00000117713 |
|
gastric adenocarcinoma |
sequence_alteration |
10.93% (115/1052) |
4 entries |
ENSG00000117713 |
|
female breast carcinoma |
frameshift_variant |
17.08% (69/404) |
3 entries |
ENSG00000117713 |
|
bladder transitional cell carcinoma |
conservative_inframe_deletion |
22.12% (165/746) |
3 entries |
ENSG00000117713 |
|
colon adenocarcinoma |
conservative_inframe_deletion |
9.385% (142/1513) |
4 entries |
ENSG00000117713 |
|
bladder carcinoma |
frameshift_variant |
18.37% (106/577) |
2 entries |
ENSG00000117713 |
|
cecum adenocarcinoma |
missense_variant |
13.64% (39/286) |
3 entries |
ENSG00000117713 |
|
Endometrial Endometrioid Adenocarcinoma |
sequence_alteration |
30.34% (311/1025) |
4 entries |
ENSG00000117713 |
|
Endometrial Endometrioid Adenocarcinoma |
frameshift_variant |
30.34% (311/1025) |
7 entries |
ENSG00000117713 |
|
female breast carcinoma |
stop_gained |
17.08% (69/404) |
2 entries |
ENSG00000117713 |
|
ovarian clear cell adenocarcinoma |
amino_acid_insertion |
49.77% (109/219) |
2 entries |
ENSG00000117713 |
|
colon adenocarcinoma |
missense_variant |
9.385% (142/1513) |
10 entries |
ENSG00000117713 |
|
Endometrial Endometrioid Adenocarcinoma |
missense_variant |
30.34% (311/1025) |
3 entries |
ENSG00000117713 |
|
bile duct adenocarcinoma |
sequence_alteration |
12.4% (77/621) |
3 entries |
ENSG00000117713 |
|
bile duct adenocarcinoma |
missense_variant |
12.4% (77/621) |
4 entries |
ENSG00000117713 |
|
gastric adenocarcinoma |
conservative_inframe_deletion |
10.93% (115/1052) |
1 entry |
ENSG00000117713 |
|
gastric adenocarcinoma |
missense_variant |
10.93% (115/1052) |
4 entries |
ENSG00000117713 |
|
Ovarian Endometrioid Adenocarcinoma |
frameshift_variant |
25.33% (19/75) |
5 entries |
ENSG00000117713 |
|
ovarian clear cell adenocarcinoma |
frameshift_variant |
49.77% (109/219) |
5 entries |
ENSG00000117713 |
|
colorectal adenocarcinoma |
missense_variant |
10.2% (133/1304) |
5 entries |
ENSG00000117713 |
|
bile duct adenocarcinoma |
frameshift_variant |
12.4% (77/621) |
4 entries |
ENSG00000117713 |
|
cecum adenocarcinoma |
stop_gained |
13.64% (39/286) |
2 entries |
ENSG00000117713 |
|
bladder transitional cell carcinoma |
stop_gained |
22.12% (165/746) |
10 entries |
ENSG00000117713 |
|
papillary thyroid carcinoma |
sequence_alteration |
2.828% (14/495) |
1 entry |
ENSG00000117713 |
|
acute lymphoblastic leukemia |
missense_variant |
1.52% (5/329) |
3 entries |
ENSG00000117713 |
|
Mixed Lobular and Ductal Breast Carcinoma |
frameshift_variant |
9.333% (7/75) |
2 entries |
ENSG00000117713 |
|
metaplastic breast carcinoma |
stop_gained |
7.317% (6/82) |
2 entries |
ENSG00000117713 |
|
major salivary gland adenoid cystic carcinoma |
frameshift_variant |
16.0% (4/25) |
1 entry |
ENSG00000117713 |
|
lung adenocarcinoma |
stop_gained |
5.794% (150/2589) |
5 entries |
ENSG00000117713 |
|
brain glioblastoma |
missense_variant |
1.683% (21/1248) |
2 entries |
ENSG00000117713 |
|
papillary renal cell carcinoma |
sequence_alteration |
3.608% (14/388) |
1 entry |
ENSG00000117713 |
|
chronic lymphocytic leukemia |
sequence_alteration |
1.684% (15/891) |
1 entry |
ENSG00000117713 |
|
brain glioblastoma |
stop_gained |
1.683% (21/1248) |
1 entry |
ENSG00000117713 |
|
esophageal adenocarcinoma |
frameshift_variant |
9.472% (52/549) |
2 entries |
ENSG00000117713 |
|
Gallbladder Adenocarcinoma |
frameshift_variant |
10.47% (20/191) |
1 entry |
ENSG00000117713 |
|
prostate carcinoma |
missense_variant |
2.655% (12/452) |
3 entries |
ENSG00000117713 |
|
glioma |
stop_gained |
1.333% (8/600) |
1 entry |
ENSG00000117713 |
|
Endometrial Clear Cell Adenocarcinoma |
missense_variant |
15.6% (17/109) |
3 entries |
ENSG00000117713 |
|
diffuse gastric adenocarcinoma |
missense_variant |
15.45% (19/123) |
1 entry |
ENSG00000117713 |
|
breast carcinoma |
stop_gained |
6.728% (140/2081) |
8 entries |
ENSG00000117713 |
|
lung adenocarcinoma |
sequence_alteration |
5.794% (150/2589) |
5 entries |
ENSG00000117713 |
|
Anal Squamous Cell Carcinoma |
missense_variant |
2.41% (2/83) |
1 entry |
ENSG00000117713 |
|
chronic lymphocytic leukemia |
missense_variant |
1.684% (15/891) |
1 entry |
ENSG00000117713 |
|
laryngeal squamous cell carcinoma |
stop_gained |
14.63% (6/41) |
3 entries |
ENSG00000117713 |
|
esophageal adenocarcinoma |
sequence_alteration |
9.472% (52/549) |
1 entry |
ENSG00000117713 |
|
osteosarcoma |
conservative_inframe_deletion |
3.247% (5/154) |
1 entry |
ENSG00000117713 |
|
esophageal adenocarcinoma |
missense_variant |
9.472% (52/549) |
3 entries |
ENSG00000117713 |
|
Thyroid Gland Undifferentiated (Anaplastic) Carcinoma |
missense_variant |
3.86% (11/285) |
2 entries |
ENSG00000117713 |
|
Uterine Carcinosarcoma |
missense_variant |
11.11% (23/207) |
2 entries |
ENSG00000117713 |
|
acute myeloid leukemia |
stop_gained |
1.994% (25/1254) |
1 entry |
ENSG00000117713 |
|
Ampulla of Vater Carcinoma |
sequence_alteration |
2.03% (4/197) |
1 entry |
ENSG00000117713 |
|
endometrium adenocarcinoma |
missense_variant |
22.22% (8/36) |
2 entries |
ENSG00000117713 |
|
squamous cell lung carcinoma |
stop_gained |
4.176% (39/934) |
4 entries |
ENSG00000117713 |
|
small cell lung carcinoma |
frameshift_variant |
4.045% (18/445) |
2 entries |
ENSG00000117713 |
|
Hidradenocarcinoma |
stop_gained |
66.67% (2/3) |
2 entries |
ENSG00000117713 |
|
pleomorphic liposarcoma |
sequence_alteration |
22.22% (2/9) |
2 entries |
ENSG00000117713 |
|
hairy cell leukemia |
stop_gained |
14.55% (8/55) |
3 entries |
ENSG00000117713 |
|
diffuse large B-cell lymphoma |
sequence_alteration |
6.143% (25/407) |
2 entries |
ENSG00000117713 |
|
pancreatic ductal adenocarcinoma |
missense_variant |
6.734% (126/1871) |
4 entries |
ENSG00000117713 |
|
small intestinal adenocarcinoma |
frameshift_variant |
9.091% (2/22) |
2 entries |
ENSG00000117713 |
|
oral squamous cell carcinoma |
missense_variant |
3.042% (8/263) |
4 entries |
ENSG00000117713 |
|
Uterine Carcinosarcoma |
frameshift_variant |
11.11% (23/207) |
3 entries |
ENSG00000117713 |
|
Breast Carcinoma by Gene Expression Profile |
gene_fusion |
7.578% (102/1346) |
1 entry |
ENSG00000117713 |
|
HER2 Positive Breast Carcinoma |
missense_variant |
13.92% (22/158) |
2 entries |
ENSG00000117713 |
|
acute myeloid leukemia |
missense_variant |
1.994% (25/1254) |
3 entries |
ENSG00000117713 |
|
brain glioblastoma |
frameshift_variant |
1.683% (21/1248) |
1 entry |
ENSG00000117713 |
|
breast carcinoma |
frameshift_variant |
6.728% (140/2081) |
9 entries |
ENSG00000117713 |
|
small cell lung carcinoma |
missense_variant |
4.045% (18/445) |
2 entries |
ENSG00000117713 |
|
prostate adenocarcinoma |
amino_acid_insertion |
2.063% (45/2181) |
2 entries |
ENSG00000117713 |
|
squamous cell lung carcinoma |
sequence_alteration |
4.176% (39/934) |
1 entry |
ENSG00000117713 |
|
papillary thyroid carcinoma |
missense_variant |
2.828% (14/495) |
2 entries |
ENSG00000117713 |
|
esophageal squamous cell carcinoma |
frameshift_variant |
2.322% (16/689) |
2 entries |
ENSG00000117713 |
|
breast carcinoma |
gene_fusion |
6.728% (140/2081) |
1 entry |
ENSG00000117713 |
|
breast ductal adenocarcinoma |
frameshift_variant |
7.306% (128/1752) |
5 entries |
ENSG00000117713 |
|
pharyngeal squamous cell carcinoma |
stop_gained |
2.098% (3/143) |
1 entry |
ENSG00000117713 |
|
central nervous system primitive neuroectodermal neoplasm |
sequence_alteration |
1.721% (10/581) |
1 entry |
ENSG00000117713 |
|
oral squamous cell carcinoma |
sequence_alteration |
3.042% (8/263) |
2 entries |
ENSG00000117713 |
|
diffuse large B-cell lymphoma |
frameshift_variant |
6.143% (25/407) |
4 entries |
ENSG00000117713 |
|
Breast Carcinoma by Gene Expression Profile |
missense_variant |
7.578% (102/1346) |
3 entries |
ENSG00000117713 |
|
prostate adenocarcinoma |
stop_gained |
2.063% (45/2181) |
1 entry |
ENSG00000117713 |
|
laryngeal squamous cell carcinoma |
sequence_alteration |
14.63% (6/41) |
2 entries |
ENSG00000117713 |
|
esophageal adenocarcinoma |
stop_gained |
9.472% (52/549) |
4 entries |
ENSG00000117713 |
|
angioimmunoblastic T-cell lymphoma |
missense_variant |
1.869% (2/107) |
1 entry |
ENSG00000117713 |
|
clear cell renal carcinoma |
missense_variant |
3.151% (54/1714) |
8 entries |
ENSG00000117713 |
|
brain glioblastoma |
sequence_alteration |
1.683% (21/1248) |
4 entries |
ENSG00000117713 |
|
esophageal adenocarcinoma |
conservative_inframe_deletion |
9.472% (52/549) |
1 entry |
ENSG00000117713 |
|
Tracheal Adenoid Cystic Carcinoma |
stop_gained |
50.0% (2/4) |
1 entry |
ENSG00000117713 |
|
chromophobe renal cell carcinoma |
sequence_alteration |
1.351% (2/148) |
1 entry |
ENSG00000117713 |
|
lobular breast carcinoma |
sequence_alteration |
6.711% (20/298) |
2 entries |
ENSG00000117713 |
|
rectal adenocarcinoma |
stop_gained |
7.018% (40/570) |
3 entries |
ENSG00000117713 |
|
anaplastic oligodendroglioma |
frameshift_variant |
9.302% (8/86) |
2 entries |
ENSG00000117713 |
|
pancreatic neuroendocrine tumor |
missense_variant |
7.347% (18/245) |
1 entry |
ENSG00000117713 |
|
lung carcinoid tumor |
frameshift_variant |
22.22% (6/27) |
1 entry |
ENSG00000117713 |
|
skin melanoma |
frameshift_variant |
7.311% (87/1190) |
1 entry |
ENSG00000117713 |
|
metaplastic breast carcinoma |
missense_variant |
7.317% (6/82) |
1 entry |
ENSG00000117713 |
|
cervical carcinoma |
stop_gained |
26.09% (6/23) |
1 entry |
ENSG00000117713 |
|
basal cell carcinoma |
sequence_alteration |
20.59% (14/68) |
2 entries |
ENSG00000117713 |
|
squamous cell lung carcinoma |
frameshift_variant |
4.176% (39/934) |
2 entries |
ENSG00000117713 |
|
chronic lymphocytic leukemia |
stop_gained |
1.684% (15/891) |
1 entry |
ENSG00000117713 |
|
Gallbladder Adenocarcinoma |
stop_gained |
10.47% (20/191) |
2 entries |
ENSG00000117713 |
|
macroglobulinemia |
frameshift_variant |
19.35% (6/31) |
1 entry |
ENSG00000117713 |
|
melanoma |
frameshift_variant |
13.29% (21/158) |
1 entry |
ENSG00000117713 |
|
ulcerative colitis |
missense_variant |
33.33% (3/9) |
1 entry |
ENSG00000117713 |
|
lung adenocarcinoma |
missense_variant |
5.794% (150/2589) |
7 entries |
ENSG00000117713 |
|
Thyroid Gland Undifferentiated (Anaplastic) Carcinoma |
sequence_alteration |
3.86% (11/285) |
2 entries |
ENSG00000117713 |
|
pancreatic neuroendocrine tumor |
stop_gained |
7.347% (18/245) |
2 entries |
ENSG00000117713 |
|
Breast Carcinoma by Gene Expression Profile |
sequence_alteration |
7.578% (102/1346) |
2 entries |
ENSG00000117713 |
|
Duodenal Adenocarcinoma |
frameshift_variant |
11.76% (2/17) |
1 entry |
ENSG00000117713 |
|
papillary renal cell carcinoma |
frameshift_variant |
3.608% (14/388) |
2 entries |
ENSG00000117713 |
|
nasopharyngeal squamous cell carcinoma |
frameshift_variant |
4.211% (16/380) |
2 entries |
ENSG00000117713 |
|
hairy cell leukemia |
frameshift_variant |
14.55% (8/55) |
2 entries |
ENSG00000117713 |
|
Breast Carcinoma by Gene Expression Profile |
frameshift_variant |
7.578% (102/1346) |
2 entries |
ENSG00000117713 |
|
Merkel cell skin cancer |
sequence_alteration |
8.421% (8/95) |
1 entry |
ENSG00000117713 |
|
Ovarian Carcinosarcoma |
sequence_alteration |
26.32% (5/19) |
1 entry |
ENSG00000117713 |
|
breast ductal adenocarcinoma |
missense_variant |
7.306% (128/1752) |
3 entries |
ENSG00000117713 |
|
Mixed Lobular and Ductal Breast Carcinoma |
missense_variant |
9.333% (7/75) |
2 entries |
ENSG00000117713 |
|
endometrial carcinoma |
sequence_alteration |
5.983% (7/117) |
2 entries |
ENSG00000117713 |
|
kidney Wilms tumor |
missense_variant |
0.9901% (10/1010) |
2 entries |
ENSG00000117713 |
|
breast carcinoma |
missense_variant |
6.728% (140/2081) |
7 entries |
ENSG00000117713 |
|
skin melanoma |
stop_gained |
7.311% (87/1190) |
7 entries |
ENSG00000117713 |
|
papillary thyroid carcinoma |
frameshift_variant |
2.828% (14/495) |
1 entry |
ENSG00000117713 |
|
leiomyosarcoma |
missense_variant |
2.97% (3/101) |
1 entry |
ENSG00000117713 |
|
esophageal squamous cell carcinoma |
missense_variant |
2.322% (16/689) |
3 entries |
ENSG00000117713 |
|
Mixed Lobular and Ductal Breast Carcinoma |
sequence_alteration |
9.333% (7/75) |
1 entry |
ENSG00000117713 |
|
pancreatic ductal adenocarcinoma |
sequence_alteration |
6.734% (126/1871) |
4 entries |
ENSG00000117713 |
|
melanoma |
missense_variant |
13.29% (21/158) |
4 entries |
ENSG00000117713 |
|
neoplasm of mature B-cells |
sequence_alteration |
10.29% (7/68) |
1 entry |
ENSG00000117713 |
|
non-small cell lung carcinoma |
missense_variant |
6.771% (13/192) |
2 entries |
ENSG00000117713 |
|
Thyroid Gland Undifferentiated (Anaplastic) Carcinoma |
stop_gained |
3.86% (11/285) |
2 entries |
ENSG00000117713 |
|
melanoma |
conservative_inframe_deletion |
13.29% (21/158) |
1 entry |
ENSG00000117713 |
|
prostate adenocarcinoma |
sequence_alteration |
2.063% (45/2181) |
2 entries |
ENSG00000117713 |
|
anaplastic astrocytoma |
frameshift_variant |
2.273% (3/132) |
1 entry |
ENSG00000117713 |
|
endometrium adenocarcinoma |
sequence_alteration |
22.22% (8/36) |
1 entry |
ENSG00000117713 |
|
hairy cell leukemia |
missense_variant |
14.55% (8/55) |
2 entries |
ENSG00000117713 |
|
ovarian serous adenocarcinoma |
stop_gained |
1.592% (17/1068) |
3 entries |
ENSG00000117713 |
|
clear cell renal carcinoma |
stop_gained |
3.151% (54/1714) |
5 entries |
ENSG00000117713 |
|
Non-Functional Pancreatic Neuroendocrine Tumor |
missense_variant |
19.35% (6/31) |
1 entry |
ENSG00000117713 |
|
skin melanoma |
missense_variant |
7.311% (87/1190) |
10 entries |
ENSG00000117713 |
|
chromophobe renal cell carcinoma |
frameshift_variant |
1.351% (2/148) |
1 entry |
ENSG00000117713 |
|
Invasive Breast Carcinoma |
stop_gained |
8.511% (4/47) |
1 entry |
ENSG00000117713 |
|
Ampulla of Vater Carcinoma |
frameshift_variant |
2.03% (4/197) |
1 entry |
ENSG00000117713 |
|
nasopharyngeal squamous cell carcinoma |
stop_gained |
4.211% (16/380) |
3 entries |
ENSG00000117713 |
|
melanoma |
stop_gained |
13.29% (21/158) |
2 entries |
ENSG00000117713 |
|
pancreatic ductal adenocarcinoma |
frameshift_variant |
6.734% (126/1871) |
5 entries |
ENSG00000117713 |
|
osteosarcoma |
missense_variant |
3.247% (5/154) |
1 entry |
ENSG00000117713 |
|
pancreatic carcinoma |
stop_gained |
7.386% (13/176) |
1 entry |
ENSG00000117713 |
|
central nervous system primitive neuroectodermal neoplasm |
missense_variant |
1.721% (10/581) |
1 entry |
ENSG00000117713 |
|
basal cell carcinoma |
stop_gained |
20.59% (14/68) |
1 entry |
ENSG00000117713 |
|
salivary gland carcinoma |
frameshift_variant |
12.12% (4/33) |
1 entry |
ENSG00000117713 |
|
ovarian serous adenocarcinoma |
sequence_alteration |
1.592% (17/1068) |
2 entries |
ENSG00000117713 |
|
pancreatic neuroendocrine tumor |
frameshift_variant |
7.347% (18/245) |
1 entry |
ENSG00000117713 |
|
macroglobulinemia |
stop_gained |
19.35% (6/31) |
2 entries |
ENSG00000117713 |
|
Uterine Carcinosarcoma |
stop_gained |
11.11% (23/207) |
2 entries |
ENSG00000117713 |
|
Gallbladder Adenocarcinoma |
sequence_alteration |
10.47% (20/191) |
1 entry |
ENSG00000117713 |
|
cervical carcinoma |
amino_acid_insertion |
26.09% (6/23) |
1 entry |
ENSG00000117713 |
|
rectal adenocarcinoma |
missense_variant |
7.018% (40/570) |
3 entries |
ENSG00000117713 |
|
nasopharyngeal squamous cell carcinoma |
sequence_alteration |
4.211% (16/380) |
2 entries |
ENSG00000117713 |
|
diffuse gastric adenocarcinoma |
sequence_alteration |
15.45% (19/123) |
4 entries |
ENSG00000117713 |
|
lung adenocarcinoma |
frameshift_variant |
5.794% (150/2589) |
4 entries |
ENSG00000117713 |
|
hepatocellular carcinoma |
sequence_alteration |
7.575% (94/1241) |
4 entries |
ENSG00000117713 |
|
rectal adenocarcinoma |
sequence_alteration |
7.018% (40/570) |
4 entries |
ENSG00000117713 |
|
lobular breast carcinoma |
frameshift_variant |
6.711% (20/298) |
2 entries |
ENSG00000117713 |
|
small cell lung carcinoma |
sequence_alteration |
4.045% (18/445) |
3 entries |
ENSG00000117713 |
|
bile duct adenocarcinoma |
amino_acid_insertion |
12.4% (77/621) |
1 entry |
ENSG00000117713 |
|
Dysplasia in Ulcerative Colitis |
stop_gained |
50.0% (4/8) |
1 entry |
ENSG00000117713 |
|
hepatocellular carcinoma |
conservative_inframe_deletion |
7.575% (94/1241) |
1 entry |
ENSG00000117713 |
|
Ovarian Endometrioid Adenocarcinoma |
missense_variant |
25.33% (19/75) |
1 entry |
ENSG00000117713 |
|
pancreatic ductal adenocarcinoma |
stop_gained |
6.734% (126/1871) |
6 entries |
ENSG00000117713 |
|
breast carcinoma |
sequence_alteration |
6.728% (140/2081) |
7 entries |
ENSG00000117713 |
|
cervical adenocarcinoma |
frameshift_variant |
15.79% (3/19) |
1 entry |
ENSG00000117713 |
|
Uterine Carcinosarcoma |
sequence_alteration |
11.11% (23/207) |
4 entries |
ENSG00000117713 |
|
prostate carcinoma |
sequence_alteration |
2.655% (12/452) |
1 entry |
ENSG00000117713 |
|
ovarian serous adenocarcinoma |
frameshift_variant |
1.592% (17/1068) |
2 entries |
ENSG00000117713 |
|
pleomorphic liposarcoma |
missense_variant |
22.22% (2/9) |
2 entries |
ENSG00000117713 |
|
acute myeloid leukemia |
frameshift_variant |
1.994% (25/1254) |
2 entries |
ENSG00000117713 |
|
hepatocellular carcinoma |
frameshift_variant |
7.575% (94/1241) |
6 entries |
ENSG00000117713 |
|
ovarian serous adenocarcinoma |
missense_variant |
1.592% (17/1068) |
2 entries |
ENSG00000117713 |
|
lung adenocarcinoma |
conservative_inframe_deletion |
5.794% (150/2589) |
1 entry |
ENSG00000117713 |
|
clear cell renal carcinoma |
sequence_alteration |
3.151% (54/1714) |
5 entries |
ENSG00000117713 |
|
Breast Carcinoma by Gene Expression Profile |
stop_gained |
7.578% (102/1346) |
4 entries |
ENSG00000117713 |
|
diffuse gastric adenocarcinoma |
frameshift_variant |
15.45% (19/123) |
3 entries |
ENSG00000117713 |
|
Appendix Goblet Cell Carcinoid |
stop_gained |
23.81% (5/21) |
2 entries |
ENSG00000117713 |
|
hepatocellular carcinoma |
stop_gained |
7.575% (94/1241) |
4 entries |
ENSG00000117713 |
|
breast ductal adenocarcinoma |
conservative_inframe_deletion |
7.306% (128/1752) |
2 entries |
ENSG00000117713 |
|
rectal adenocarcinoma |
frameshift_variant |
7.018% (40/570) |
3 entries |
ENSG00000117713 |
|
cecum adenocarcinoma |
conservative_inframe_deletion |
13.64% (39/286) |
1 entry |
ENSG00000117713 |
|
nasopharyngeal squamous cell carcinoma |
missense_variant |
4.211% (16/380) |
2 entries |
ENSG00000117713 |
|
non-small cell lung carcinoma |
frameshift_variant |
6.771% (13/192) |
1 entry |
ENSG00000117713 |
|
neoplasm of mature B-cells |
stop_gained |
10.29% (7/68) |
3 entries |
ENSG00000117713 |
|
nasopharyngeal squamous cell carcinoma |
amino_acid_insertion |
4.211% (16/380) |
1 entry |
ENSG00000117713 |
|
non-small cell lung carcinoma |
stop_gained |
6.771% (13/192) |
4 entries |
ENSG00000117713 |
|
Merkel cell skin cancer |
missense_variant |
8.421% (8/95) |
3 entries |
ENSG00000117713 |
|
Gallbladder Adenocarcinoma |
missense_variant |
10.47% (20/191) |
3 entries |
ENSG00000117713 |
|
breast ductal adenocarcinoma |
sequence_alteration |
7.306% (128/1752) |
3 entries |
ENSG00000117713 |
|
lung carcinoid tumor |
stop_gained |
22.22% (6/27) |
1 entry |
ENSG00000117713 |
|
Borderline Ovarian Mucinous Tumor |
frameshift_variant |
20.0% (2/10) |
1 entry |
ENSG00000117713 |
|
basal cell carcinoma |
missense_variant |
20.59% (14/68) |
2 entries |
ENSG00000117713 |
|
squamous cell lung carcinoma |
missense_variant |
4.176% (39/934) |
3 entries |
ENSG00000117713 |
|
Endometrial Undifferentiated Carcinoma |
stop_gained |
33.33% (2/6) |
2 entries |
ENSG00000117713 |
|
anaplastic oligodendroglioma |
missense_variant |
9.302% (8/86) |
1 entry |
ENSG00000117713 |
|
Dysplasia in Ulcerative Colitis |
missense_variant |
50.0% (4/8) |
1 entry |
ENSG00000117713 |
|
prostate adenocarcinoma |
missense_variant |
2.063% (45/2181) |
3 entries |
ENSG00000117713 |
|
breast carcinoma |
amino_acid_insertion |
6.728% (140/2081) |
1 entry |
ENSG00000117713 |
|
hemangioblastoma |
missense_variant |
8.571% (3/35) |
1 entry |
ENSG00000117713 |
|
Thyroid Gland Undifferentiated (Anaplastic) Carcinoma |
frameshift_variant |
3.86% (11/285) |
2 entries |
ENSG00000117713 |
|
kidney Wilms tumor |
sequence_alteration |
0.9901% (10/1010) |
1 entry |
ENSG00000117713 |
|
central nervous system primitive neuroectodermal neoplasm |
frameshift_variant |
1.721% (10/581) |
1 entry |
ENSG00000117713 |
|
nasal cavity and paranasal sinus carcinoma |
stop_gained |
13.04% (3/23) |
2 entries |
ENSG00000117713 |
|
medullary thyroid gland carcinoma |
sequence_alteration |
2.703% (2/74) |
2 entries |
ENSG00000117713 |
|
hepatocellular carcinoma |
amino_acid_insertion |
7.575% (94/1241) |
1 entry |
ENSG00000117713 |
|
small cell lung carcinoma |
stop_gained |
4.045% (18/445) |
2 entries |
ENSG00000117713 |
|
acute myeloid leukemia |
sequence_alteration |
1.994% (25/1254) |
1 entry |
ENSG00000117713 |
|
papillary renal cell carcinoma |
missense_variant |
3.608% (14/388) |
1 entry |
ENSG00000117713 |
|
endometrial carcinoma |
stop_gained |
5.983% (7/117) |
1 entry |
ENSG00000117713 |
|
anaplastic oligodendroglioma |
stop_gained |
9.302% (8/86) |
2 entries |
ENSG00000117713 |
|
Merkel cell skin cancer |
frameshift_variant |
8.421% (8/95) |
1 entry |
ENSG00000117713 |
|
cervical carcinoma |
sequence_alteration |
26.09% (6/23) |
1 entry |
ENSG00000117713 |
|
lobular breast carcinoma |
stop_gained |
6.711% (20/298) |
2 entries |
ENSG00000117713 |
|
clear cell renal carcinoma |
frameshift_variant |
3.151% (54/1714) |
8 entries |
ENSG00000117713 |
|
Endometrial Clear Cell Adenocarcinoma |
frameshift_variant |
15.6% (17/109) |
3 entries |
ENSG00000117713 |
|
Mixed Lobular and Ductal Breast Carcinoma |
stop_gained |
9.333% (7/75) |
1 entry |
ENSG00000117713 |
|
Breast Carcinoma by Gene Expression Profile |
amino_acid_insertion |
7.578% (102/1346) |
1 entry |
ENSG00000117713 |
|
Breast Carcinoma by Gene Expression Profile |
conservative_inframe_deletion |
7.578% (102/1346) |
1 entry |
ENSG00000117713 |
|
hairy cell leukemia |
sequence_alteration |
14.55% (8/55) |
2 entries |
ENSG00000117713 |
|
pancreatic neuroendocrine tumor |
sequence_alteration |
7.347% (18/245) |
1 entry |
ENSG00000117713 |
|
oral squamous cell carcinoma |
conservative_inframe_deletion |
3.042% (8/263) |
1 entry |
ENSG00000117713 |
|
breast ductal adenocarcinoma |
stop_gained |
7.306% (128/1752) |
8 entries |
ENSG00000117713 |
|
T-cell acute lymphoblastic leukemia |
sequence_alteration |
0.5249% (2/381) |
1 entry |
ENSG00000117713 |
|
hepatocellular carcinoma |
missense_variant |
7.575% (94/1241) |
8 entries |
ENSG00000117713 |
|
cervical carcinoma |
frameshift_variant |
26.09% (6/23) |
1 entry |
ENSG00000117713 |
|
HER2 Positive Breast Carcinoma |
sequence_alteration |
13.92% (22/158) |
1 entry |
ENSG00000117713 |
|
HER2 Positive Breast Carcinoma |
gene_fusion |
13.92% (22/158) |
1 entry |
ENSG00000117713 |
|
gastric intestinal type adenocarcinoma |
conservative_inframe_deletion |
19.23% (30/156) |
1 entry |
ENSG00000117713 |
|
head and neck squamous cell carcinoma |
missense_variant |
0.5109% (4/783) |
2 entries |
ENSG00000117713 |
|
Burkitts lymphoma |
stop_gained |
8.14% (7/86) |
1 entry |
ENSG00000117713 |
|
anaplastic oligodendroglioma |
sequence_alteration |
9.302% (8/86) |
2 entries |
ENSG00000117713 |
|
esophageal squamous cell carcinoma |
stop_gained |
2.322% (16/689) |
2 entries |
ENSG00000117713 |
|
laryngeal squamous cell carcinoma |
frameshift_variant |
14.63% (6/41) |
1 entry |
ENSG00000117713 |
|
esophageal squamous cell carcinoma |
sequence_alteration |
2.322% (16/689) |
2 entries |
ENSG00000117713 |
|
prostate adenocarcinoma |
frameshift_variant |
2.063% (45/2181) |
3 entries |
ENSG00000117713 |
|
rectal adenocarcinoma |
conservative_inframe_deletion |
7.018% (40/570) |
1 entry |
ENSG00000117713 |
|
diffuse large B-cell lymphoma |
stop_gained |
6.143% (25/407) |
2 entries |
ENSG00000117713 |
|
neoplasm of mature B-cells |
missense_variant |
10.29% (7/68) |
1 entry |
ENSG00000117713 |
|
Endometrial Clear Cell Adenocarcinoma |
sequence_alteration |
15.6% (17/109) |
2 entries |
ENSG00000117713 |
|
salivary gland carcinoma |
sequence_alteration |
12.12% (4/33) |
1 entry |
ENSG00000117713 |
|
diffuse large B-cell lymphoma |
missense_variant |
6.143% (25/407) |
3 entries |
ENSG00000117713 |
|
papillary thyroid carcinoma |
stop_gained |
2.828% (14/495) |
1 entry |
ENSG00000117713 |
|
lobular breast carcinoma |
missense_variant |
6.711% (20/298) |
1 entry |
ENSG00000117713 |
|
endometrium adenocarcinoma |
frameshift_variant |
22.22% (8/36) |
1 entry |
ENSG00000117713 |
|
diffuse gastric adenocarcinoma |
stop_gained |
15.45% (19/123) |
5 entries |
ENSG00000117713 |
|
Burkitts lymphoma |
frameshift_variant |
8.14% (7/86) |
2 entries |
ENSG00000117713 |
|
skin melanoma |
sequence_alteration |
7.311% (87/1190) |
3 entries |
ENSG00000117713 |
|
Ovarian Endometrioid Adenocarcinoma |
conservative_inframe_deletion |
25.33% (19/75) |
1 entry |
ENSG00000117713 |
|
Endometrial Clear Cell Adenocarcinoma |
stop_gained |
15.6% (17/109) |
4 entries |
ENSG00000117713 |
|
angioimmunoblastic T-cell lymphoma |
sequence_alteration |
1.869% (2/107) |
1 entry |
ENSG00000117713 |
|
Parotid Gland Squamous Cell Carcinoma |
sequence_alteration |
100.0% (1/1) |
1 entry |
ENSG00000117713 |
|
chronic myelomonocytic leukemia |
missense_variant |
1.053% (1/95) |
1 entry |
ENSG00000117713 |
|
metaplastic breast carcinoma |
conservative_inframe_deletion |
7.317% (6/82) |
1 entry |
ENSG00000117713 |
|
Gastric Neuroendocrine Tumor G1 |
missense_variant |
11.11% (1/9) |
1 entry |
ENSG00000117713 |
|
anaplastic oligoastrocytoma |
frameshift_variant |
3.448% (1/29) |
1 entry |
ENSG00000117713 |
|
HER2 Positive Breast Carcinoma |
conservative_inframe_deletion |
13.92% (22/158) |
1 entry |
ENSG00000117713 |
|
Duodenal Adenocarcinoma |
sequence_alteration |
11.76% (2/17) |
1 entry |
ENSG00000117713 |
|
ovarian serous adenocarcinoma |
conservative_inframe_deletion |
1.592% (17/1068) |
1 entry |
ENSG00000117713 |
|
embryonal rhabdomyosarcoma |
missense_variant |
1.124% (1/89) |
1 entry |
ENSG00000117713 |
|
neuroendocrine carcinoma |
stop_gained |
14.29% (1/7) |
1 entry |
ENSG00000117713 |
|
Appendix Adenocarcinoma |
stop_gained |
1.299% (1/77) |
1 entry |
ENSG00000117713 |
|
Pleural Epithelioid Mesothelioma |
sequence_alteration |
0.5% (1/200) |
1 entry |
ENSG00000117713 |
|
Pleural Mesothelioma |
missense_variant |
1.258% (2/159) |
1 entry |
ENSG00000117713 |
|
salivary gland adenoid cystic carcinoma |
frameshift_variant |
3.175% (2/63) |
1 entry |
ENSG00000117713 |
|
non-small cell lung carcinoma |
conservative_inframe_deletion |
6.771% (13/192) |
1 entry |
ENSG00000117713 |
|
hemangioblastoma |
conservative_inframe_deletion |
8.571% (3/35) |
1 entry |
ENSG00000117713 |
|
Non-Functional Pancreatic Neuroendocrine Tumor |
amino_acid_insertion |
19.35% (6/31) |
1 entry |
ENSG00000117713 |
|
acute lymphoblastic leukemia |
sequence_alteration |
1.52% (5/329) |
1 entry |
ENSG00000117713 |
|
oral squamous cell carcinoma |
frameshift_variant |
3.042% (8/263) |
1 entry |
ENSG00000117713 |
|
malignant epithelioid mesothelioma |
frameshift_variant |
8.333% (1/12) |
1 entry |
ENSG00000117713 |
|
Pleural Epithelioid Mesothelioma |
missense_variant |
0.5% (1/200) |
1 entry |
ENSG00000117713 |
|
ovarian carcinoma |
stop_gained |
10.0% (1/10) |
1 entry |
ENSG00000117713 |
|
T-cell acute lymphoblastic leukemia |
missense_variant |
0.5249% (2/381) |
1 entry |
ENSG00000117713 |
|
neoplasm |
stop_gained |
6.667% (2/30) |
1 entry |
ENSG00000117713 |
|
prostate carcinoma |
frameshift_variant |
2.655% (12/452) |
1 entry |
ENSG00000117713 |
|
Ovarian Endometriosis |
missense_variant |
50.0% (2/4) |
1 entry |
ENSG00000117713 |
|
B-cell neoplasm |
stop_gained |
5.556% (1/18) |
1 entry |
ENSG00000117713 |
|
ovarian adenocarcinoma |
stop_gained |
10.0% (1/10) |
1 entry |
ENSG00000117713 |
|
endometrial carcinoma |
missense_variant |
5.983% (7/117) |
1 entry |
ENSG00000117713 |
|
renal cell carcinoma |
conservative_inframe_deletion |
1.471% (1/68) |
1 entry |
ENSG00000117713 |
|
endometrium adenocarcinoma |
stop_gained |
22.22% (8/36) |
1 entry |
ENSG00000117713 |
|
Malignant Ovarian Mixed Epithelial Tumor |
frameshift_variant |
10.0% (1/10) |
1 entry |
ENSG00000117713 |
|
diffuse gastric adenocarcinoma |
conservative_inframe_deletion |
15.45% (19/123) |
1 entry |
ENSG00000117713 |
|
Signet Ring Cell Gastric Adenocarcinoma |
frameshift_variant |
33.33% (1/3) |
1 entry |
ENSG00000117713 |
|
nasal cavity and paranasal sinus carcinoma |
missense_variant |
13.04% (3/23) |
1 entry |
ENSG00000117713 |
|
prostate carcinoma |
stop_gained |
2.655% (12/452) |
1 entry |
ENSG00000117713 |
|
primary peritoneal carcinoma (disease) |
frameshift_variant |
100.0% (1/1) |
1 entry |
ENSG00000117713 |
|
T-cell acute lymphoblastic leukemia |
frameshift_variant |
0.5249% (2/381) |
1 entry |
ENSG00000117713 |
|
Meningeal Melanocytoma |
missense_variant |
5.263% (1/19) |
1 entry |
ENSG00000117713 |
|
salivary gland carcinoma |
stop_gained |
12.12% (4/33) |
1 entry |
ENSG00000117713 |
|
Undifferentiated Ovarian Carcinoma |
frameshift_variant |
28.57% (2/7) |
1 entry |
ENSG00000117713 |
|
hepatocellular carcinoma |
transcript_ablation |
7.575% (94/1241) |
1 entry |
ENSG00000117713 |
|
salivary gland adenoid cystic carcinoma |
stop_gained |
3.175% (2/63) |
1 entry |
ENSG00000117713 |
|
Malignant Urinary System Neoplasm |
frameshift_variant |
100.0% (1/1) |
1 entry |
ENSG00000117713 |
|
dedifferentiated chondrosarcoma |
sequence_alteration |
5.882% (1/17) |
1 entry |
ENSG00000117713 |
|
neuroendocrine carcinoma |
missense_variant |
14.29% (1/7) |
1 entry |
ENSG00000117713 |
|
embryonal rhabdomyosarcoma |
sequence_alteration |
1.124% (1/89) |
1 entry |
ENSG00000117713 |
|
lung carcinoid tumor |
sequence_alteration |
22.22% (6/27) |
1 entry |
ENSG00000117713 |
|
Tonsillar Squamous Cell Carcinoma |
stop_gained |
11.11% (1/9) |
1 entry |
ENSG00000117713 |
|
Malignant Ovarian Mixed Epithelial Tumor |
conservative_inframe_deletion |
10.0% (1/10) |
1 entry |
ENSG00000117713 |
|
Chordoma |
missense_variant |
7.143% (1/14) |
1 entry |
ENSG00000117713 |
|
unspecified peripheral T-cell lymphoma |
frameshift_variant |
5.263% (1/19) |
1 entry |
ENSG00000117713 |
|
head and neck squamous cell carcinoma |
stop_gained |
0.5109% (4/783) |
1 entry |
ENSG00000117713 |
|
colon adenoma |
missense_variant |
5.882% (1/17) |
1 entry |
ENSG00000117713 |
|
cervical adenocarcinoma |
sequence_alteration |
15.79% (3/19) |
1 entry |
ENSG00000117713 |
|
Mantle cell lymphoma |
sequence_alteration |
3.774% (2/53) |
1 entry |
ENSG00000117713 |
|
Kidney Oncocytoma |
missense_variant |
2.778% (1/36) |
1 entry |
ENSG00000117713 |
|
small cell carcinoma |
conservative_inframe_deletion |
33.33% (1/3) |
1 entry |
ENSG00000117713 |
|
angioimmunoblastic T-cell lymphoma |
stop_gained |
1.869% (2/107) |
1 entry |
ENSG00000117713 |
|
Invasive Breast Carcinoma |
frameshift_variant |
8.511% (4/47) |
1 entry |
ENSG00000117713 |
|
pseudomyxoma peritonei |
frameshift_variant |
10.0% (1/10) |
1 entry |
ENSG00000117713 |
|
major salivary gland adenoid cystic carcinoma |
missense_variant |
16.0% (4/25) |
1 entry |
ENSG00000117713 |
|
Ampulla of Vater Carcinoma |
stop_gained |
2.03% (4/197) |
1 entry |
ENSG00000117713 |
|
Mantle cell lymphoma |
frameshift_variant |
3.774% (2/53) |
1 entry |
ENSG00000117713 |
|
Pleural Mesothelioma |
sequence_alteration |
1.258% (2/159) |
1 entry |
ENSG00000117713 |
|
Undifferentiated Ovarian Carcinoma |
stop_gained |
28.57% (2/7) |
1 entry |
ENSG00000117713 |
|
Bladder Small Cell Neuroendocrine Carcinoma |
missense_variant |
33.33% (1/3) |
1 entry |
ENSG00000117713 |
|
marginal zone B-cell lymphoma |
stop_gained |
3.175% (2/63) |
1 entry |
ENSG00000117713 |
|
Gastrointestinal stromal tumor |
missense_variant |
1.974% (3/152) |
1 entry |
ENSG00000117713 |
|
Parotid Gland Adenoid Cystic Carcinoma |
frameshift_variant |
14.29% (2/14) |
1 entry |
ENSG00000117713 |
|
metaplastic breast carcinoma |
frameshift_variant |
7.317% (6/82) |
1 entry |
ENSG00000117713 |
|
Ovarian Carcinosarcoma |
stop_gained |
26.32% (5/19) |
1 entry |
ENSG00000117713 |
|
ovarian mucinous adenocarcinoma |
frameshift_variant |
3.03% (1/33) |
1 entry |
ENSG00000117713 |
|
Ovarian Endometriosis |
frameshift_variant |
50.0% (2/4) |
1 entry |
ENSG00000117713 |
|
cervical carcinoma |
missense_variant |
26.09% (6/23) |
1 entry |
ENSG00000117713 |
|
melanoma |
sequence_alteration |
13.29% (21/158) |
1 entry |
ENSG00000117713 |
|
Parotid Gland Adenoid Cystic Carcinoma |
stop_gained |
14.29% (2/14) |
1 entry |
ENSG00000117713 |
|
Hidradenocarcinoma |
sequence_alteration |
66.67% (2/3) |
1 entry |
ENSG00000117713 |
|
Fibrolamellar Carcinoma |
stop_gained |
5.263% (1/19) |
1 entry |
ENSG00000117713 |
|
Conjunctival Melanoma |
sequence_alteration |
25.0% (1/4) |
1 entry |
ENSG00000117713 |
|
Krukenberg Tumor |
frameshift_variant |
100.0% (1/1) |
1 entry |
ENSG00000117713 |
|
prostate adenocarcinoma |
conservative_inframe_deletion |
2.063% (45/2181) |
1 entry |
ENSG00000117713 |
|
osteosarcoma |
frameshift_variant |
3.247% (5/154) |
1 entry |
ENSG00000117713 |
|
follicular thyroid carcinoma |
sequence_alteration |
1.429% (1/70) |
1 entry |
ENSG00000117713 |
|
gastric tubular adenocarcinoma |
frameshift_variant |
50.0% (1/2) |
1 entry |
ENSG00000117713 |
|
Hodgkins lymphoma |
stop_gained |
3.39% (2/59) |
1 entry |
ENSG00000117713 |
|
testicular seminoma |
amino_acid_insertion |
1.282% (1/78) |
1 entry |
ENSG00000117713 |
|
Ovarian Carcinosarcoma |
frameshift_variant |
26.32% (5/19) |
1 entry |
ENSG00000117713 |
|
Conjunctival Melanoma |
missense_variant |
25.0% (1/4) |
1 entry |
ENSG00000117713 |
|
Gastrointestinal stromal tumor |
sequence_alteration |
1.974% (3/152) |
1 entry |
ENSG00000117713 |
|
carcinoid tumor |
sequence_alteration |
16.67% (1/6) |
1 entry |
ENSG00000117713 |
|
nasal cavity and paranasal sinus carcinoma |
sequence_alteration |
13.04% (3/23) |
1 entry |
ENSG00000117713 |
|
Invasive Breast Carcinoma |
missense_variant |
8.511% (4/47) |
1 entry |
ENSG00000117713 |
|
dedifferentiated chondrosarcoma |
stop_gained |
5.882% (1/17) |
1 entry |
ENSG00000117713 |
|
large cell lung carcinoma |
conservative_inframe_deletion |
10.53% (2/19) |
1 entry |
ENSG00000117713 |
|
Gastrointestinal stromal tumor |
conservative_inframe_deletion |
1.974% (3/152) |
1 entry |
ENSG00000117713 |
|
Salivary Gland Carcinoma ex Pleomorphic Adenoma |
frameshift_variant |
8.333% (2/24) |
1 entry |
ENSG00000117713 |
|
skin melanoma |
amino_acid_insertion |
7.311% (87/1190) |
1 entry |
ENSG00000117713 |
|
hemangioblastoma |
frameshift_variant |
8.571% (3/35) |
1 entry |
ENSG00000117713 |
|
non-small cell lung carcinoma |
sequence_alteration |
6.771% (13/192) |
1 entry |
ENSG00000117713 |
|
undifferentiated pleomorphic sarcoma |
frameshift_variant |
1.613% (1/62) |
1 entry |
ENSG00000117713 |
|
Ovarian Endometriosis |
stop_gained |
50.0% (2/4) |
1 entry |
ENSG00000117713 |
|
kidney Wilms tumor |
frameshift_variant |
0.9901% (10/1010) |
1 entry |
ENSG00000117713 |
|
leiomyosarcoma |
stop_gained |
2.97% (3/101) |
1 entry |
ENSG00000117713 |
|
Pancreatic Acinar Cell Carcinoma |
sequence_alteration |
5.882% (2/34) |
1 entry |
ENSG00000117713 |
|
small cell lung carcinoma |
amino_acid_insertion |
4.045% (18/445) |
1 entry |
ENSG00000117713 |
|
Benign Ovarian Mucinous Tumor |
frameshift_variant |
20.0% (1/5) |
1 entry |
ENSG00000117713 |
|
Salivary Gland Carcinoma ex Pleomorphic Adenoma |
stop_gained |
8.333% (2/24) |
1 entry |
ENSG00000117713 |
|
pancreatic carcinoma |
amino_acid_insertion |
7.386% (13/176) |
1 entry |
ENSG00000117713 |
|
Parathyroid Gland Carcinoma |
stop_gained |
2.857% (1/35) |
1 entry |
ENSG00000117713 |
|
Non-Functional Pancreatic Neuroendocrine Tumor |
sequence_alteration |
19.35% (6/31) |
1 entry |
ENSG00000117713 |
|
osteosarcoma |
sequence_alteration |
3.247% (5/154) |
1 entry |
ENSG00000117713 |
|
neuroendocrine carcinoma |
sequence_alteration |
14.29% (1/7) |
1 entry |
ENSG00000117713 |
|
lung carcinoma |
conservative_inframe_deletion |
4.0% (6/150) |
1 entry |
ENSG00000117713 |
|
large cell lung carcinoma |
stop_gained |
10.53% (2/19) |
1 entry |
ENSG00000117713 |
|
ovarian serous adenocarcinoma |
amino_acid_insertion |
1.592% (17/1068) |
1 entry |
ENSG00000117713 |
|
testicular seminoma |
sequence_alteration |
1.282% (1/78) |
1 entry |
ENSG00000117713 |
|
Malignant Ovarian Mixed Epithelial Tumor |
stop_gained |
10.0% (1/10) |
1 entry |
ENSG00000117713 |
|
Hepatoblastoma |
missense_variant |
6.667% (1/15) |
1 entry |
ENSG00000117713 |
|
pharyngeal squamous cell carcinoma |
missense_variant |
2.098% (3/143) |
1 entry |
ENSG00000117713 |
|
Hodgkins lymphoma |
frameshift_variant |
3.39% (2/59) |
1 entry |
ENSG00000117713 |
|
pseudomyxoma peritonei |
sequence_alteration |
10.0% (1/10) |
1 entry |
ENSG00000117713 |
|
marginal zone B-cell lymphoma |
missense_variant |
3.175% (2/63) |
1 entry |
ENSG00000117713 |
|
alveolar rhabdomyosarcoma |
stop_gained |
1.538% (1/65) |
1 entry |
ENSG00000117713 |
|
Thymic Squamous Cell Carcinoma |
stop_gained |
3.571% (1/28) |
1 entry |
ENSG00000117713 |
|
Malignant Ovarian Mixed Epithelial Tumor |
sequence_alteration |
10.0% (1/10) |
1 entry |
ENSG00000117713 |
|
Pancreatic Acinar Cell Carcinoma |
frameshift_variant |
5.882% (2/34) |
1 entry |
ENSG00000117713 |
|
basal cell carcinoma |
frameshift_variant |
20.59% (14/68) |
1 entry |
ENSG00000117713 |
|
adenosquamous lung carcinoma |
missense_variant |
4.545% (1/22) |
1 entry |
ENSG00000117713 |
|
Pleural Mesothelioma |
stop_gained |
1.258% (2/159) |
1 entry |
ENSG00000117713 |
|
Anal Squamous Cell Carcinoma |
sequence_alteration |
2.41% (2/83) |
1 entry |
ENSG00000117713 |
|
Cortisol-Producing Adrenal Cortex Adenoma |
stop_gained |
0.8065% (1/124) |
1 entry |
ENSG00000117713 |
|
Gastrointestinal stromal tumor |
frameshift_variant |
1.974% (3/152) |
1 entry |
ENSG00000117713 |
|
head and neck squamous cell carcinoma |
frameshift_variant |
0.5109% (4/783) |
1 entry |
ENSG00000117713 |
|
neoplasm of mature B-cells |
frameshift_variant |
10.29% (7/68) |
1 entry |
ENSG00000117713 |
|
Mantle cell lymphoma |
missense_variant |
3.774% (2/53) |
1 entry |
ENSG00000117713 |
|
angiosarcoma |
amino_acid_insertion |
2.083% (1/48) |
1 entry |
ENSG00000117713 |
|
adrenal cortex carcinoma |
missense_variant |
0.5291% (1/189) |
1 entry |
ENSG00000117713 |
|
Thymic Carcinoma |
frameshift_variant |
6.667% (1/15) |
1 entry |
ENSG00000117713 |
|
medullary thyroid gland carcinoma |
frameshift_variant |
2.703% (2/74) |
1 entry |
ENSG00000117713 |
|
leiomyosarcoma |
sequence_alteration |
2.97% (3/101) |
1 entry |
ENSG00000117713 |
|
carcinoid tumor |
frameshift_variant |
16.67% (1/6) |
1 entry |
ENSG00000117713 |
|
kidney Wilms tumor |
stop_gained |
0.9901% (10/1010) |
1 entry |
ENSG00000117713 |
|
lung carcinoma |
frameshift_variant |
4.0% (6/150) |
1 entry |
ENSG00000117713 |
|
laryngeal squamous cell carcinoma |
conservative_inframe_deletion |
14.63% (6/41) |
1 entry |
ENSG00000117713 |
|
endometrial carcinoma |
frameshift_variant |
5.983% (7/117) |
1 entry |
ENSG00000117713 |
|
angiosarcoma |
sequence_alteration |
2.083% (1/48) |
1 entry |
ENSG00000117713 |
|
Hodgkins lymphoma |
sequence_alteration |
3.39% (2/59) |
1 entry |
ENSG00000117713 |
|
major salivary gland adenoid cystic carcinoma |
sequence_alteration |
16.0% (4/25) |
1 entry |
ENSG00000117713 |
|
Pancreatic Acinar Cell Carcinoma |
missense_variant |
5.882% (2/34) |
1 entry |